NYSE:TAK
Takeda Pharmaceutical Company Limited Stock News
$13.35
+0.320 (+2.46%)
At Close: May 31, 2024
Takeda to Present at The 39th Annual J.P. Morgan Healthcare Conference
07:00am, Monday, 11'th Jan 2021
OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE: 4502/NYSE: TAK) (“Takeda”) will present virtually at the 39th Annual J.P. Morgan Healthcare Conference
3 Low Price-Book Ratio Stock Picks
11:06am, Sunday, 10'th Jan 2021
Screening the market for securities whose market capitalization surpasses $2 billion and whose price-book ratios are trading below 1.5 could yield a higher likelihood of unearthing value opportunities
Takeda Completes Sale of Select Non-Core Assets to Cheplapharm
02:00am, Tuesday, 05'th Jan 2021
OSAKA, Japan--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced the completion of its previously-announced sale of a portfolio of select prescri
Seagen Earns Top Honors from Key Biotech Publication
10:25am, Thursday, 31'st Dec 2020
Seagen, Inc. (SGEN) has recently been named Biotech of the Year by leading industry publication Biopharma Dive, and investors would no doubt agree. Shares of the Seattle-area firm are up nearly 65% ye
Takeda Furthers Innovation-Focused Strategy in China with Sale of Select Non-Core Assets to Hasten for $322 million USD
02:00am, Monday, 21'st Dec 2020
OSAKA, Japan--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that it has entered into an agreement to divest a portfolio of non-core prescrip
CAMBRIDGE, Mass. & OSAKA, Japan--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) has approved the supplement
OSAKA, Japan--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that the United States (U.S.) Food and Drug Administration (FDA) has accepted fo
Japan's Takeda says drug pipeline to lift sales to $48 billion in next decade
09:46pm, Tuesday, 08'th Dec 2020
Japan's Takeda Pharmaceutical Co said on Wednesday its drug pipeline is poised to drive annual sales up by more than 50%, to 5 trillion yen ($48.01 billion) in the next decade.
Takeda's Pipeline Has Potential to Contribute Significantly to Revenue Growth Over Next Decade
07:15pm, Tuesday, 08'th Dec 2020
OSAKA, Japan--(BUSINESS WIRE)--As part of its Wave 1 Pipeline Market Opportunity Call, Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) provided an update on its pipeline portf
CAMBRIDGE, Mass. and OSAKA, Japan--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced the U.S. availability of myPKFiT® for ADYNOVATE® [Antihem
Takeda Completes Sale of Select OTC and Non-Core Assets to Celltrion in Asia Pacific
06:00pm, Monday, 30'th Nov 2020
OSAKA, Japan--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced the completion of its previously-announced sale of a portfolio of select product
World's Leading Life Science Companies Now Enrolling COMMUNITY, A Global, Platform Trial For Hospitalized Patients With COVID-19
04:45pm, Monday, 30'th Nov 2020
THOUSAND OAKS, Calif., Nov. 30, 2020 /PRNewswire/ -- Three members of the COVID R&D Alliance - Amgen Inc. (NASDAQ: AMGN), Takeda Pharmaceutical Co. Ltd. (NYSE: TAK), and UCB (Euronext BR: UCB) - today
Egle Therapeutics Identifies First Novel Regulatory T-cell Targets in Research Alliance with Takeda
05:30am, Thursday, 26'th Nov 2020
PARIS--(BUSINESS WIRE)--Egle Therapeutics SAS (Egle), an emerging biotechnology company focused on developing first-in class immunotherapies targeting immune suppressor regulatory T-cells (Tregs) for
Takeda Pharma's Venkayya on Global Race for Covid Vaccines
12:22am, Monday, 23'rd Nov 2020
Nov.22 -- Rajeev Venkayya, president of the global vaccine business unit of Japan's Takeda Pharmaceutical Co., discusses the latest developments in the global race for Covid-19 vaccines. The company s
Which Coronavirus Vaccine Maker Is Poised to Be the Top Supplier?
09:42am, Saturday, 14'th Nov 2020
The numbers are close, but two players stand out at the moment.